Categories: News

Psychedelic Therapy in Australia Likely To Cost Thousands

Australian patients will have legal access to the psychedelic drugs psilocybin and MDMA under a plan announced by regulators last month. But with no approved source of the drug available to therapists, patients can face charges of tens of thousands of dollars to receive promising treatment.

Last month, the Therapeutic Goods Administration (TGA), the Australian government’s medicines and treatments regulator, announced that qualified psychiatrists will be able to prescribe the hallucinogens psilocybin and MDMA for the treatment of certain mental health conditions starting later this year. announced that it will be However, agencies have not approved products containing promising psychedelics, forcing mental health professionals to source the drugs themselves. Without it, psychiatrists estimate that patients will have to pay as much as A$25,000 (about $17,000), and even more for psychedelic-assisted therapy.

“For a real patient, it might cost $25,000, $30,000 to treat.” Dr. Stephen Bright saidSenior Lecturer at Edith Cowan University and Director of the charity Psychedelic Research in Science and Medicine.

“Frankly, I don’t think these treatments will be widely available for 12 to 18 months after July 1,” he added. “The tightly controlled treatment means very few psychologists are raising their hands. There are a few clinics opening, but I don’t think the floodgates will open.”

Dr. Paul Liknitsky, head of the Clinical Psychedelic Lab at Monash University, said last month that he and other mental health professionals will partner with investors to open a psychedelic assist therapy clinic in Melbourne. made it clear that However, training requirements for therapists and detailed guidelines for such treatments have not yet been issued by government regulators.

“It lacks detailed clarity that will help us understand how TGA will unfold. We are concerned, but cautiously optimistic.”

Rickneitzky said he and his colleagues would help establish a protocol that would set high standards for ethical and effective psychedelic supportive therapy. He warned that he might not receive treatment.

“Based on decades of best practice development, a wise and safe treatment approach includes considerable screening, psychotherapy, and other support. A typical course of treatment over several months costs 25,000 people. It could be on the order of $10,000 plus or minus $10,000,” he said.

Psychedelic-assisted therapy shows promise

Ongoing research shows that psilocybin, the primary psychoactive compound in magic mushrooms, is an effective treatment for several serious mental health conditions, including PTSD, major depressive disorder, anxiety disorders and substance abuse disorders. has been shown to be possible.a Studies published in 2020 The peer-reviewed journal JAMA Psychiatry found that psilocybin-assisted psychotherapy was a fast-acting and effective treatment for a group of 24 participants with major depressive disorder.

another study Psilocybin treatment, announced in 2016, determined to significantly and sustainably reduce depression and anxiety in patients with life-threatening cancer. study It was published in the magazine nature medicine We have determined that MDMA, commonly known as ecstasy, is a highly effective and safe treatment for patients with severe PTSD.

But Professor Chris Langmead of the Monash Institute of Pharmaceutical Sciences says it’s unlikely public health agencies will cover the cost of such treatments until further studies, including cost-benefit analyses, are completed.

“We are aiming for a significant increase in research and funding so that we can conduct research, clinical studies, and the development of practice. [to ensure] This is not a purely market-driven solution that the most disadvantaged are missing out on,” he said. “The TGA has put Australia at the forefront of the world and we need to take this opportunity and make the most of it.”

Gillinder Bedi, an associate professor at the University of Melbourne, said the lack of clinical staff trained in psychedelic supportive therapy is also making it difficult for patients to get treatment.

“The infrastructure is set up. “If you put two clinical psychologists in the room for her eight hours, [Medicare] Billing rate of $120 per hour – This is not what people charge, it’s what they charge $200 to $300.I think it should be higher [than $25,000].

“No matter how you look at it, it will take longer and cost more than other treatments. Bedi added. “But at least in the early stages, it will be for people with money.”

Alexandra Solorio

Introducing Alexandra, an accomplished cannabis writer who has passionately pursued her craft for a decade. Through a decade-long journey, Alexandra has cultivated a profound connection with the cannabis world, translating her expertise into captivating prose. From unraveling the plant's rich history to exploring its therapeutic marvels and legal evolution, she has adeptly catered to both connoisseurs and newcomers. An unwavering advocate, Alexandra's words not only enlighten but also advocate responsible cannabis use, establishing her as an indispensable industry voice over the past ten years.

Recent Posts

Colorado Voters Face 14 Ballot Measures Spanning Fentanyl Sentencing And Tax Overhauls

Fourteen Measures Headed to Colorado Voters Colorado voters will decide 14 statewide ballot measures this November. The count matches 2024…

31 minutes ago

Rock Hill Residents Sue Proper Brands Over Skunky Cannabis Facility Odor

Lawsuit Filed Over Facility Odor Residents of Rock Hill are suing Proper Brands, arguing that a "skunky" smell from the…

3 hours ago

Workplace Drug Testing Fails To Keep Pace With Cannabis Reform Expert Warns

Expert Warning On Outdated Testing Dr Georges Petitjean has warned that workplace drug testing has failed to keep pace with…

13 hours ago

Shore House Canna Returns With Third Annual Fall Fest At Cape May Farm

Event Details Shore House Canna, an adult-use dispensary in West Cape May, New Jersey, will host its 3rd Annual Fall…

16 hours ago

Sabalenka Halts US Open Match Over Strong Cannabis Smell From Crowd

Sabalenka Stops Play Over Cannabis Smell Top seed Aryna Sabalenka briefly halted her US Open third-round match against Kamilla Rakhimova…

22 hours ago

CBD of Denver Signs Share Exchange Agreement To Advance BioCannabis Merger

CBDD Signs Definitive Agreement to Acquire BioCannabis CBD of Denver, Inc. (OTCID: CBDD) announced on September 15, 2026 that it…

1 day ago

NUG Magazine is published and distributed by NUG Magazine LLC. Established in 2009,
We have been bringing you the latest and up to date information from the cannabis market.
All contents are for entertainment and educational purposes only and are intended for mature audiences.

Products

Search Nug Magazine!

Advertisement

Instagram @Nugmagazine

[instagram-feed]

About NUG

We are the #1 Source for your Cannabis news and information